Claims for Patent: 10,723,730

Summary for Patent: 10,723,730

Title:	Solid forms of a selective CDK4/6 inhibitor
Abstract:	This invention relates to the crystalline free base of acetyl-8-cyclopentyl-5-methyl-2-(5-piperazin-1-yl-pyridin-2-ylamino)-8H-p- yrido[2,3-d]pyrimidin-7-one, formula (1) having improved properties, to pharmaceutical compositions and dosage forms comprising the free base, and to methods for making and using such compounds, compositions and dosage forms in the treatment of cell proliferative diseases, such as cancer. ##STR00001##
Inventor(s):	Chekal; Brian Patrick (Niantic, CT), Ide; Nathan D. (Mystic, CT)
Assignee:	Pfizer Inc. (New York, NY)
Application Number:	15/808,577
Patent Claims:	1. A crystalline free base of 6-acetyl-8-cyclopentyl-5-methyl-2-(5-piperazin-1-yl-pyridin-2-ylamino)-8H- -pyrido[2,3-d]pyrimidin-7-one, having a powder X-ray diffraction pattern comprising peaks at diffraction angles (2.theta.) of 8.0.+-.0.2, 10.1.+-.0.2 and 11.5.+-.0.2 and a primary particle size distribution characterized by a D90 value of from about 30 .mu.m to about 65 .mu.m. 2. The free base of claim 1, having a powder X-ray diffraction pattern comprising peaks at diffraction angles (2.theta.) of 8.0.+-.0.2, 10.1.+-.0.2, 10.3.+-.0.2, and 11.5.+-.0.2. 3. The free base of claim 1, having a powder X-ray diffraction pattern comprising peaks at diffraction angles (2.theta.) essentially the same as shown in FIG. 1. 4. The free base of claim 1, having a .sup.13C solid state NMR spectrum comprising the following resonance (ppm) values: 12.5 ppm.+-.0.2 ppm. 5. The free base of claim 4, having a .sup.13C solid state NMR spectrum comprising the following resonance (ppm) values: 12.5 ppm and 112.4 ppm.+-.0.2 ppm. 6. The free base of claim 5, having a .sup.13C solid state NMR spectrum comprising the following resonance (ppm) values: 12.5 ppm, 112.4 ppm and 143.2 ppm.+-.0.2 ppm. 7. A crystalline free base of 6-acetyl-8-cyclopentyl-5-methyl-2-(5-piperazin-1-yl-pyridin-2-ylamino)-8H- -pyrido[2,3-d]pyrimidin-7-one, having a powder X-ray diffraction pattern comprising peaks at diffraction angles (2.theta.) of 8.0.+-.0.2, 10.1.+-.0.2 and 11.5.+-.0.2 and a volume mean diameter characterized by a D[4,3] value of from about 15 .mu.m to about 40 .mu.m. 8. The free base of claim 7, having a powder X-ray diffraction pattern comprising peaks at diffraction angles (2.theta.) of 8.0.+-.0.2, 10.1.+-.0.2, 10.3.+-.0.2, and 11.5.+-.0.2. 9. The free base of claim 7, having a powder X-ray diffraction pattern comprising peaks at diffraction angles (2.theta.) essentially the same as shown in FIG. 1. 10. The free base of claim 7, having a .sup.13C solid state NMR spectrum comprising the following resonance (ppm) values: 12.5 ppm.+-.0.2 ppm. 11. The free base of claim 10, having a .sup.13C solid state NMR spectrum comprising the following resonance (ppm) values: 12.5 ppm and 112.4 ppm.+-.0.2 ppm. 12. The free base of claim 11, having a .sup.13C solid state NMR spectrum comprising the following resonance (ppm) values: 12.5 ppm, 112.4 ppm and 143.2 ppm.+-.0.2 ppm. 13. A pharmaceutical composition comprising the free base of claim 1 and at least one pharmaceutically acceptable carrier, diluent or excipient. 14. A pharmaceutical composition comprising the free base of claim 7 and at least one pharmaceutically acceptable carrier, diluent or excipient. 15. A crystalline free base of 6-acetyl-8-cyclopentyl-5-methyl-2-(5-piperazin-1-yl-pyridin-2-ylamino)-8H- -pyrido[2,3-d]pyrimidin-7-one, having a powder X-ray diffraction pattern comprising peaks at diffraction angles (2.theta.) of 8.0.+-.0.2, 10.1.+-.0.2 and 11.5.+-.0.2 and a volume mean diameter characterized by a D[4,3] value of from about 15 .mu.m to about 30 .mu.m. 16. The free base of claim 15, having a powder X-ray diffraction pattern comprising peaks at diffraction angles (2.theta.) of 8.0.+-.0.2, 10.1.+-.0.2, 10.3.+-.0.2, and 11.5.+-.0.2. 17. The free base of claim 15, having a powder X-ray diffraction pattern comprising peaks at diffraction angles (2.theta.) essentially the same as shown in FIG. 1. 18. The free base of claim 15, having a .sup.13C solid state NMR spectrum comprising the following resonance (ppm) values: 12.5 ppm.+-.0.2 ppm. 19. The free base of claim 18, having a .sup.13C solid state NMR spectrum comprising the following resonance (ppm) values: 12.5 ppm and 112.4 ppm.+-.0.2 ppm. 20. The free base of claim 19, having a .sup.13C solid state NMR spectrum comprising the following resonance (ppm) values: 12.5 ppm, 112.4 ppm and 143.2 ppm.+-.0.2 ppm. 21. A pharmaceutical composition comprising the free base of claim 15 and at least one pharmaceutically acceptable carrier, diluent or excipient.